Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Antic, Darko

Oral and Poster Abstracts
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I

Bleeding and Clotting, bleeding disorders, Lymphoid Leukemias, CLL, Diseases, SARS-CoV-2/COVID-19, Infectious Diseases, thrombotic disorders, Lymphoid Malignancies, Human, Study Population

Darko Antic, PhD^1,2^*, Natasa Milic³^*, Thomas Chatzikonstantinou^4,5^*, Lydia Scarfo, MD⁶^*, Vladimir Otasevic, MD²^*, Nina Rajovic³^*, David Allsup⁷^*, Alejandro Alonso Cabrero⁸^*, Martin Andres⁹^*, Monica Baile Gonzales¹⁰^*, Antonella Capasso¹¹^*, Rosa Collado^12,13^*, Raul Cordoba, MD, PhD¹⁴, Carolina Cuéllar-García¹⁵^*, Juan Gonzalo Correa¹⁶^*, Lorenzo De Paoli¹⁷^*, Maria Rosaria De Paolis¹⁸^*, Giovanni Del Poeta, MD¹⁹^*, Maria Dimou²⁰, Michael Doubek, MD, PhD^21,22, Maria Efstathopoulou²³^*, Shaimaa El-Ashwah²⁴^*, Alicia Enrico²⁵^*, Blanca Espinet, PhD²⁶^*, Lucia Farina²⁷^*, Angela Ferrari²⁸^*, Myriam Foglietta²⁹^*, Alberto Lopez-Garcia¹⁴^*, Jose A. Garcia-Marco³⁰, Rocío García-Serra^12,13^*, Massimo Gentile, MD³¹^*, Eva Gimeno²⁶^*, Maria Gomes da Silva³²^*, Odit Gutwein^33,34^*, Yervand Hakobyan³⁵^*, Yair Herishanu³⁶^*, José Ángel Hernández-Rivas³⁷^*, Tobias Herold, MD³⁸, Gilad Itchaki³⁹^*, Ozren Jaksic, MD, PhD⁴⁰, Ann Janssens, MD, PhD⁴¹^*, Оlga B. Kalashnikova⁴²^*, Elżbieta Kalicińska⁴³^*, Arnon P. Kater, MD, PhD⁴⁴, Sabina Kersting, MD, PhD⁴⁵^*, Maya Koren-Michowitz, MD^34,46, Jorge Labrador Gomez⁴⁷^*, Deepesh Lad⁴⁸^*, Luca Laurenti, MD^49,50^*, Alberto Fresa, MD^49,51^*, Mark-David Levin⁵², Carlota Mayor Bastida^8,53^*, Lara Malerba⁵⁴^*, Roberto Marasca, MD⁵⁵, Monia Marchetti⁵⁶^*, Juan Marquet⁵⁷^*, Biljana Mihaljevic^1,2^*, Ivana Milosevic⁵⁸^*, Fatima Mirás⁵⁹^*, Marta Morawska^60,61^*, Marina Motta, MD⁶²^*, Talha Munir, MBBS, MRCP, FRCPath, PhD⁶³^*, Roberta Murru, MD⁶⁴^*, Raquel Nunes⁶⁵^*, Jacopo Olivieri⁶⁶^*, Miguel Arturo Pavlovsky⁶⁷, Inga S. Piskunova⁶⁸^*, Viola Maria Popov⁶⁹^*, Francesca Maria Quaglia⁷⁰^*, Giulia Quaresmini⁷¹^*, Gianluigi Reda, MD⁷²^*, Gian Matteo Rigolin⁷³^*, Amit Shrestha⁷⁴^*, Martin Šimkovič⁷⁵^*, Svetlana Smirnova⁶⁸^*, Martin Špaček⁷⁶^*, Paolo Sportoletti, MD⁷⁷^*, Oana Stanca⁷⁸^*, Niki Stavroyianni⁷⁹^*, Doreen Te Raa⁸⁰^*, Kristina Tomic²^*, Sanne Tonino⁸¹^*, Livio Trentin⁸², Ellen Van Der Spek⁸³^*, Michel van Gelder⁸⁴, Marzia Varettoni, MD⁸⁵^*, Andrea Visentin, MD, PhD⁸²^*, Candida Vitale⁸⁶^*, Vojin Vukovic²^*, Ewa Wasik-Szczepanek⁸⁷^*, Tomasz Wróbel⁸⁸, Lucrecia Yanez San Segundo⁸⁹, Mohamed A Yassin, MBBS, MSC, CABM, MSC, FACP⁹⁰, Marta Coscia⁹¹^*, Alessandro Rambaldi, MD⁷¹, Emili Montserrat¹⁶^*, Robin Foà⁹²^*, Antonio Cuneo⁷³^*, Marc Carrier, MD, MSc⁹³, Paolo Ghia, MD, PhD⁹⁴ and Kostas Stamatopoulos, MD⁴

¹Faculty of Medicine, University of Belgrade, Belgrade, Serbia
²Lymphoma Center, Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia
³Department of Medical Statistics and Informatics, Medical Faculty, University of Belgrade, Belgrade, Serbia
⁴Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
⁵Hematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece
⁶Università Vita-salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy
⁷Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, ENG, United Kingdom
⁸Haematology department, Hospital Universitario de La Princesa, Madrid, Spain
⁹Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
¹⁰Hematology Department. University Hospital of Salamanca-IBSAL, Salamanca, Spain
¹¹IRCCS Ospedale San Raffaele, Milano, Italy
¹²Department of Hematology, Hospital General Universitario, Valencia, Spain
¹³Fundación de Investigación del Hospital General Universitario, Valencia, Spain
¹⁴Department of Hematology, Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
¹⁵Hematology Unit Terrassa Hospital, Terrasa, Spain
¹⁶Hospital Clínic de Barcelona, Barcelona, Spain
¹⁷Division of Internal Medicine, Hematology Unit, ASL Vercelli, Vercelli, Italy
¹⁸UOC Ematologia PO Vito Fazzi Lecce, Lecce, Italy
¹⁹Hematology, Department of Biomedicine, University Tor Vergata Roma, Italy, Rome, Italy
²⁰1st Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Athens, Greece
²¹Department of Internal Medicine - Hematology and Oncology, Medical Faculty MU and University Hospital Brno, Brno, Czech Republic
²²Department of Internal Medicine - Hematology and Oncology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic
²³Department of Haematology Athens Medical Center-Psychikon Branch, Athens, Greece
²⁴Clinical Hematology Unit, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
²⁵Hospital Italiano La Plata, La Plata, Argentina
²⁶Department of Hematology, Hospital del Mar, Barcelona, Spain
²⁷Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
²⁸Hematology Unit, Azienda Unità Sanitaria Locale – IRCCS, Reggio Emilia, Italy
²⁹SC Ematologia, AO S. Croce e Carle, Cuneo, Italy
³⁰Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain
³¹Hematology Unit AO Cosenza, Cosenza, Italy
³²Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
³³Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
³⁴Department of Hematology, Shamir Medical Center, Zerifin, Israel
³⁵Hematology Center after Prof. Yeolyan MH RA, Yerevan, Armenia
³⁶Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, ISR
³⁷Department of Hematology, Infanta Leonor University Hospital, Madrid, Spain
³⁸Laboratory for Leukemia Diagnostics, Department of Medicine III, Ludwig-maximilians-Universitaet (LMU), Munich, Bavaria, Germany
³⁹Division of Hematology, Rabin Medical Center, Petah Tikva, and the Sackler School of Medicine, Tel-Aviv University, Petah Tikva, Israel
⁴⁰Division of Hematolog, Dubrava University Hospital, Zagreb, Croatia
⁴¹Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
⁴²Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation, St. Petersburg, Russian Federation
⁴³Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation Wroclaw Medical University, Pasteura Street 4, 50-367 Wrocław, Poland
⁴⁴Dept of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
⁴⁵Department of Hematology, Haga Teaching Hospital, The Hague, Netherlands
⁴⁶Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
⁴⁷Hematology Department, Unit Research, Complejo Asistencial Universitario de Burgos, Burgos, Spain
⁴⁸Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
⁴⁹Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy
⁵⁰Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
⁵¹Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
⁵²Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, Netherlands
⁵³Spanish Society of Haematology and hemotherapy (SEHH: Sociedad Española de Hematología y hemoterapia), Madrid, Spain
⁵⁴Hematology and Stem Cell Transplant Center Marche Nord Hospital, Pesaro, Italy
⁵⁵Dept of Medical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy
⁵⁶Hematology Unit & TMO Center, AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
⁵⁷Hematology Department Ramón y Cajal University Hospital, Madrid, Spain
⁵⁸University of Novi Sad, Faculty of Medicine, Clinical Centre of Vojvodina, Novi Sad, Serbia
⁵⁹Hematology Department Hospital Universitario 12 de Octubre, Madrid, Spain
⁶⁰Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland
⁶¹Hematology Department, St. John's Cancer Center, Lublin, Poland
⁶²S.C. Ematologia ASST Spedali Civili, Brescia, Italy
⁶³Consultant Haematologist, St James's Hospital, Leeds, United Kingdom
⁶⁴Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS G. Brotzu, Cagliari, Italy
⁶⁵Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal
⁶⁶Hematology Clinic, ASUFC, Udine, Italy
⁶⁷FUNDALEU, Clinical research center Buenos Aires, Buenos Aires, Argentina
⁶⁸Consultative Hematology Department with a Day Hospital for Intensive High-Dose Chemotherapy, National Research Center for Hematology, Moscow, Russian Federation
⁶⁹Hematology Department Colentina Clinical Hospital, Bucharest, Romania
⁷⁰Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
⁷¹Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
⁷²Hematology unit, Hematology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, Milan, Italy
⁷³St. Anna University Hospital, Ferrara, Italy
⁷⁴Hematology Unit, Nepal Cancer Hospital & Research Center, Lalitpur, Nepal
⁷⁵4th Department of Internal Medicine – Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
⁷⁶1st Department of Medicine - Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
⁷⁷Department of Medicine and Surgery, Institute of Hematology and Center for Hemato-Oncological Research, Ospedale S. Maria della Misericordia, Perugia, Italy
⁷⁸"Carol Davila" University of Medicine and Pharmacy - Hematology Department from Coltea Clinical Hospital, Bucharest, Romania
⁷⁹Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
⁸⁰Department of hematology, Gelderse Vallei Ede, Ede, Netherlands
⁸¹Dept of Hematology, Lymmcare, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
⁸²Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy
⁸³Rijnstate hospital, department of internal medicine Arnhem, Arnhem, Netherlands
⁸⁴Dept internal medicine, Maastricht University Medical Center, Maastricht, Netherlands
⁸⁵Division of Hematology Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
⁸⁶Division of Hematology, A.O.U. Cittàdella Salute e dellaScienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, TX, Italy
⁸⁷Dept. Hematooncology and Bone Marrow Transplantation Medical University in Lublin, Lublin, Poland
⁸⁸Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation Wroclaw Medical University, Wroclaw, Poland
⁸⁹University Hospital and Research Institute of Marqués de Valdecilla (IDIVAL), Santander, Spain
⁹⁰Department of Medical Oncology/ Hematology Section, National Centre For Cancer Care & Research, Doha, Qatar
⁹¹Division of Hematology, A.O.U. Cittàdella Salute e dellaScienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
⁹²Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
⁹³Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
⁹⁴Universita' Vita-Salute San Raffaele C.F. 97187560152, Milano, MI, Italy

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19.

Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting.

Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR=1.022, 95%CI 1.007‒1.038 and OR=1.025, 95%CI 1.001‒1.051, respectively), while thromboprophylaxis use was protective (OR=0.199, 95%CI 0.061‒0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR=1.062, 95%CI 1.017-1.109 and OR=2.438, 95%CI 1.023-5.813, respectively).

Conclusions: Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration.

Paolo Ghiaand Kostas Stamatopoulos contributed equally to this work.

Disclosures: Scarfo: AbbVie, AstraZeneca, Janssen, Beigene, Lilly: Honoraria; BeiGene, Janssen: Other: Travel Grant; Octapharma: Speakers Bureau. Cordoba: Janssen: Other: Speaker; Astra Zeneca: Other: Speaker; Lilly: Consultancy; Beigene: Consultancy; Janssen: Consultancy; Astra Zeneca: Consultancy. Doubek: AOP Orphan: Consultancy, Research Funding; AbbVie: Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Honoraria. García-Serra: Novartis: Other: received educational activity; Abbvie: Other: received educational activity. Gomes da Silva: Gilead Genesis: Research Funding; AstraZeneca: Research Funding; Janssen, Gilead Sciences, MSD, Celgene, Roche, Takeda, Novartis, ADC Therapeutics: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees; Janssen: Speakers Bureau. Hernández-Rivas: Rovi: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Speakers Bureau; Lilly: Membership on an entity's Board of Directors or advisory committees. Itchaki: AstraZeneca: Consultancy; Abbvie: Consultancy; Janssen: Consultancy. Jaksic: Johnson and Johnson: Speakers Bureau; Abbvie: Speakers Bureau; Astra Zeneca: Consultancy, Speakers Bureau. Janssens: Genmab: Current Employment; Abbvie: Consultancy, Other: Travel Grants, Speakers Bureau; Amgen: Consultancy, Other: travel grants, Speakers Bureau; Astra-Zeneca: Consultancy, Speakers Bureau; Beigene: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Sobi: Consultancy, Speakers Bureau; Sanofi Genzyme: Consultancy, Speakers Bureau; Roche: Consultancy; Celgene: Other: travel grants. Kater: Astra Zeneca, BMS, Roche/Gennetech, Janssen, Abbvie, LAVA: Membership on an entity's Board of Directors or advisory committees; Janssen, LAVA: Patents & Royalties: Pending; Abbvie, Astra Zeneca, BMS, Janssen, Roche/Genentech: Research Funding; Abbvie, Astra Zeneca, Janssen: Other: Speakers fee; Amsterdam UMC, University of Amsterdam: Current Employment. Levin: AbbVie, Roche and Janssen: Other: Travel expenses. Munir: Janssen, AstraZeneca, Alexion, Sobi, Novartis, Roche, Abbvie, Gilead: Honoraria; Janssen, AstraZeneca, Alexion, Abbvie, Novartis, Roche: Membership on an entity's Board of Directors or advisory committees. Pavlovsky: AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Raffo: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Other; AbbVie: Other: Conference; Janssen: Other: Conference; Janssen: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees. Reda: Janssen, Abbive, Astra Zeneca, Beigene: Consultancy. Rigolin: Abbvie: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria; Gilead: Honoraria, Research Funding. Šimkovič: Janssen-Cilag, Gilead, Roche, AstraZeneca, Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grants. Tonino: Roche: Honoraria; Incyte: Honoraria; Takeda: Honoraria. Varettoni: ABBVIE: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; ASTRAZENECA: Membership on an entity's Board of Directors or advisory committees; BEIGENE: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; JANNSEN: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses. Visentin: Janssen, Abbvie, CSL Behring: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy; Gilead: Consultancy; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Wróbel: GSK: Honoraria; Janssen: Honoraria; Amgen: Honoraria, Research Funding; Takeda: Honoraria; Beigene: Honoraria; Novartis: Honoraria; Abbvie: Honoraria; Gilead: Honoraria; Celgen/BMS: Honoraria; Roche: Honoraria, Research Funding. Rambaldi: Amgen: Honoraria; Pfizer: Honoraria; Astellas: Honoraria; ABBVIE: Honoraria; Jazz: Honoraria; Kite-Gilead: Honoraria; Novartis: Honoraria; Incyte: Honoraria; Roche: Honoraria; Janssen: Honoraria; Celgene-BMS: Honoraria; Omeros: Honoraria. Carrier: Pfizer: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy; BMS: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Leo Pharma: Consultancy, Honoraria, Research Funding. Ghia: MSD: Consultancy, Honoraria; Roche: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Lilly/Loxo: Consultancy, Honoraria. Stamatopoulos: Janssen: Research Funding; AbbVie: Research Funding.

See more of: 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I
See more of: Oral and Poster Abstracts

<< Previous Abstract | Next Abstract >>

^*signifies non-member of ASH

1175 Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL